851
Views
4
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Still grasping at straws: donanemab in Alzheimer’s disease

Pages 797-801 | Received 03 May 2021, Accepted 22 Jun 2021, Published online: 08 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Rita Khoury, Amy Gallop, Kelsey Roberts, Noam Grysman, Jiaxi Lu & George T. Grossberg. (2022) Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon?. Expert Opinion on Pharmacotherapy 23:11, pages 1305-1323.
Read now

Articles from other publishers (3)

Ying Hao, Mingrui Dong, Yingtong Sun, Xiaohui Duan & Wenquan Niu. (2023) Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease. Frontiers in Neurology 14.
Crossref
Parth Sharma, Ritchu Babbar, Twinkle Sharma, Piyush Madaan, Sandeep Arora & Vishnu Nayak Badavath. (2023) Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry 23:1, pages 53-66.
Crossref
Albert Garcia-Romeu, Sean Darcy, Hillary Jackson, Toni White & Paul Rosenberg. 2022. Disruptive Psychopharmacology. Disruptive Psychopharmacology 287 317 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.